We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Industry groups such as AdvaMed argued the caps would negatively impact manufacturers’ ability to pay for future R&D investments and job creation. Read More
Nativis entered into a license agreement in 2017 for the development of the technology for the treatment of adults with glioblastoma multiforme in the Japanese market. Read More